Merck Launches Online Platform Fertility.com

Food and Healthcare Press Releases Tuesday July 3, 2018 15:15
DARMSTADT, Germany--3 Jul--PRNewswire/InfoQuest
Not intended for U.S. based media
  • Fertility.com is the gateway to two online portals:
  • Offering the latest scientific information to healthcare professionals in the advancing field of fertility
  • Supporting women, men and couples who are looking for information about fertility and/or undergoing fertility treatment
(Photo: https://mma.prnewswire.com/media/713837/Merck_Fertility_com.jpg )
(Photo: https://mma.prnewswire.com/media/713838/Fertility_com.jpg )
Merck, a leading science and technology company, today announces the launch of the new online portal fertility.com. Fertility.com is the entrance to access two unique and bespoke portals:
  • Fertility.com/hcp; developed for fertility Healthcare Professionals (HCPs)
  • Fertility.com/support; created for women, men and couples who are looking for information about fertility and/or are undergoing fertility treatment

The Healthcare Professional Portal (fertility.com/hcp) offers a wide range of resources relevant to physicians' daily practice. On the portal, healthcare professionals can find key medical and scientific content. This includes the latest news, publications and developments in the field of fertility as well as expert opinion videos and educational materials. The portal also provides the opportunity to discover more about Merck's therapeutics, technologies and services.

The Patient Support Portal (fertility.com/support) has been created to provide a profound source of information for women, men and couples who are trying or have been trying to conceive. The portal is designed to support patients at every step of their fertility journey, including educational materials that help them understand fertility and treatment options. They can also find lifestyle advice to improve their chances for success.

Fertility.com is designed with convenience and easy navigation in mind, ensuring that patients and physicians can easily access the information they need, anytime and everywhere. This new online platform demonstrates Merck's commitment to continuing to support people trying to conceive, whilst also offering HCPs a scientific platform with the latest advances in reproductive medicine.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of EUR 15.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

(Logo: http://mma.prnewswire.com/media/472778/Merck_Logo.jpg )
Your Contact: Dr. Raphaela Farrenkopf, +49-6151-72-2274
Source: Merck

Latest Press Release

Takeda, Microsoft and EURORDIS release report with action plan to help rare disease community shorten the diagnostic odyssey

- Global Commission's recommendations focus on three solution pathways that leverage technology to address key elements of the rare disease diagnostic odyssey - Rare diseases remain undiagnosed as patients struggle to navigate complex health systems to...

Pivotal Phase III Data for BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

- JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for patients with advanced renal cell...

ISABS เตรียมจัดการประชุมว่าด้วยการแพทย์ส่วนบุคคลที่โครเอเชีย พร้อมเชิญเจ้าของรางวัลโนเบลร่วมบรรยาย

International Society for Applied Biological Sciences (ISABS) ร่วมกับ Mayo Clinic และ St. Catherine Hospital เตรียมจัดการประชุม "ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine" ครั้งที่ 11...

ISABS: Personalized Medicine Conference With Nobel Laureates to Be Held in Split, Croatia

International Society for Applied Biological Sciences (ISABS), Mayo Clinic and St. Catherine Hospital are organizing "11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine"(http://www.isabs.net)...

Beijing Intellectual Property Court Confirms Judgment Against Wuxi Hisky Medical for Patent Infringement of Technology Used for Echosens# FibroScan(R), Imposes Damages Orders Halt to Manufacturing and Sales

Echosens, an innovative high-technology company offering the FibroScan family of products dedicated to assessment of chronic liver disease, today announces that the Beijing Intellectual Property Court has confirmed judgment against Wuxi Hisky Medical,...

Related Topics